TABLE 2.

Plasma Aβ42, Aβ40, Aβ42/Aβ40, t-tau, and 18F-florbetapir PET SUVR for NC, SCD, MCI, and non-AD dementia in individuals with Aβ-PET (−).

Plasma biomarkers	NC (n = 145)	SCD (n = 50)	MCI (n = 68)	Non-AD dementia (n = 22)	F (P-value)
Aβ42 (pg/ml)	9.93 ± 3.01	9.30 ± 2.72	10.83 ± 2.89	11.65 ± 4.41	6.02 (0.001)
Aβ40 (pg/ml)	183.86 ± 44.15	184.61 ± 36.19	192.59 ± 52.05	209.01 ± 52.52	1.93 (0.124)
Aβ42/Aβ40 (ratio)	0.0557 ± 0.0172	0.0514 ± 0.0139	0.0585 ± 0.0200	0.0555 ± 0.0144	2.10 (0.101)
T-tau (pg/ml)	2.50 ± 1.23	2.29 ± 0.90	2.42 ± 1.00	2.32 ± 0.92	0.27 (0.844)
18F-florbetapir PET SUVR	1.19 ± 0.07	1.19 ± 0.07	1.17 ± 0.08	1.16 ± 0.09	0.18 (0.905)

NC, cognitively normal controls; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, Alzheimer’s disease; 18F-florbetapir PET, 18F-florbetapir positron emission tomography; SUVR, standard uptake value ratios. P-values were adjusted for age, sex, and education years with general linear models. The bold values represented the values with statistical significance.